Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.60USD
26 Jul 2017
Change (% chg)

$0.02 (+3.46%)
Prev Close
$0.58
Open
$0.57
Day's High
$0.60
Day's Low
$0.57
Volume
422,446
Avg. Vol
1,134,981
52-wk High
$0.97
52-wk Low
$0.37

CYTR.OQ

Chart for CYTR.OQ

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)

Overall

Beta: 2.27
Market Cap(Mil.): $87.89
Shares Outstanding(Mil.): 152.05
Dividend: --
Yield (%): --

Financials

  CYTR.OQ Industry Sector
P/E (TTM): -- 211.50 15.59
EPS (TTM): -0.58 -- --
ROI: -110.83 -8.04 -8.43
ROE: -205.16 -9.41 -8.00

BRIEF-Cytrx announces update on regulatory pathway for aldoxorubicin in soft tissue sarcomas

* Cytrx announces update on the regulatory pathway for aldoxorubicin in soft tissue sarcomas

Jun 08 2017

BRIEF-Cytrx reports Q1 loss per share $0.10

* Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin

May 10 2017

BRIEF-Cytrx Corp prices $15 mln public offering of common stock

* Cytrx Corporation announces pricing of $15 million public offering of common stock

Apr 28 2017

BRIEF-Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin

* Cytrx announces FDA agreement on regulatory pathway to approval for Aldoxorubicin in soft tissue sarcomas

Apr 19 2017

Earnings vs. Estimates